Abstract
Curcumin, a polyphenolic compound derived from the dietary spice turmeric, possesses diverse pharmacologic effects including anti-inflammatory, anti-oxidant, anti-proliferative and anti-angiogenic activities. Accumulating experimental evidence suggests that curcumin interferes with a variety of molecular targets and processes involved in cancer. Further, data obtained in multiple preclinical models, as well as in preliminary clinical trials, have documented minimal toxicity of curcumin, even at relatively high doses. However, the clinical advancement of this promising molecule has been hindered by its poor water solubility, short biological half-life, and low bioavailability after oral administration. A variety of approaches are being pursued to overcome these limitations, which include synthesis of curcumin analogues, the use of adjuvants (e.g. piperine), and the development of improved delivery platforms for the parental compound, including liposomal, nanoparticulated and phospholipid complex formulations of curcumin. This review is intended to provide the reader an update on the bioavailability and pharmacokinetic pitfalls of free curcumin, and a comprehensive cataloging of ongoing approaches that have been undertaken to resolve these issues, with the goal of harnessing the true potential of this anti-cancer agent in the clinical arena.
Keywords: Curcumin, polymeric nanoparticle, nanocurcumin, cancer, bioavailability
Current Drug Discovery Technologies
Title: Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum
Volume: 6 Issue: 3
Author(s): Savita Bisht and Anirban Maitra
Affiliation:
Keywords: Curcumin, polymeric nanoparticle, nanocurcumin, cancer, bioavailability
Abstract: Curcumin, a polyphenolic compound derived from the dietary spice turmeric, possesses diverse pharmacologic effects including anti-inflammatory, anti-oxidant, anti-proliferative and anti-angiogenic activities. Accumulating experimental evidence suggests that curcumin interferes with a variety of molecular targets and processes involved in cancer. Further, data obtained in multiple preclinical models, as well as in preliminary clinical trials, have documented minimal toxicity of curcumin, even at relatively high doses. However, the clinical advancement of this promising molecule has been hindered by its poor water solubility, short biological half-life, and low bioavailability after oral administration. A variety of approaches are being pursued to overcome these limitations, which include synthesis of curcumin analogues, the use of adjuvants (e.g. piperine), and the development of improved delivery platforms for the parental compound, including liposomal, nanoparticulated and phospholipid complex formulations of curcumin. This review is intended to provide the reader an update on the bioavailability and pharmacokinetic pitfalls of free curcumin, and a comprehensive cataloging of ongoing approaches that have been undertaken to resolve these issues, with the goal of harnessing the true potential of this anti-cancer agent in the clinical arena.
Export Options
About this article
Cite this article as:
Bisht Savita and Maitra Anirban, Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum, Current Drug Discovery Technologies 2009; 6 (3) . https://dx.doi.org/10.2174/157016309789054933
DOI https://dx.doi.org/10.2174/157016309789054933 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploring the Management of Statin Intolerant Patients: 2016 and Beyond
Current Vascular Pharmacology Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Cardiotoxicity of 5-Fluorouracil
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Modulation by Licofelone and Celecoxib of Experimentally Induced Cancer and Preneoplastic Lesions in Mice Exposed to Cigarette Smoke
Current Cancer Drug Targets Botulinum Toxin: Pharmacology and Clinical Developments: A Literature Review
Medicinal Chemistry Patenting of Nanopharmaceuticals in Drug Delivery: No Small Issue
Recent Patents on Drug Delivery & Formulation Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry Review of Structures Containing Fullerene-C60 for Delivery of Antibacterial Agents. Multitasking model for Computational Assessment of Safety Profiles
Current Bioinformatics PHB in Cardiovascular and Other Diseases: Present Knowledge and Implications
Current Drug Targets Three-Dimensional Tissue Models for Drug Discovery and Toxicology
Recent Patents on Biotechnology Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Fc-fusion Proteins in Therapy: An Updated View
Current Medicinal Chemistry Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Current Medicinal Chemistry Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds Novel Methods for the Non-Invasive Administration of DNA Therapeutics and Vaccines
Current Drug Delivery Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases
Anti-Cancer Agents in Medicinal Chemistry Identification and Characterization of New Proteins in Podocyte Dysfunction of Membranous Nephropathy by Proteomic Analysis of Renal Biopsy
Current Pharmacogenomics and Personalized Medicine Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery